NasdaqGS:NBIXBiotechs
Neurocrine Biosciences (NBIX) Valuation Check After New Mid Stage VMAT2 Inhibitor Trial Update
Why this new trial matters for Neurocrine Biosciences (NBIX) shareholders
Neurocrine Biosciences (NBIX) has kicked off a Phase 2 trial of NBI-1065890, a next generation VMAT2 inhibitor for tardive dyskinesia. This marks fresh pipeline activity that investors may watch closely.
See our latest analysis for Neurocrine Biosciences.
The Phase 2 trial news lands at a time when the share price, at US$136.06, has seen a 30 day share price return of 4.07% decline and a 1 year total shareholder return...